3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Conditions
Febrile Neutropenia
6
Neutropenia
4
Neoplasms
4
Fever
4
Infections
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Recurrence
1
Pseudomonas Infections
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Liver Neoplasms
1
Interventions
pembrolizumab
155
Gemcitabine
139
Capecitabine
121
Paclitaxel
118
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
92
Cisplatin
89
Irinotecan
87
Carboplatin
84
Radiosurgery
83
Cyclophosphamide
70
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
Vancomycin
×
Clear all
NCT04208958
2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2
Completed
56 enrolled
11 charts